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The supercritical fluid technology has been target of many pharmaceuticals investigations in particles 
production for almost 35 years. This is due to the great advantages it offers over others technologies 
currently used for the same purpose. A brief history is presented, as well the classification of 
supercritical technology based on the role that the supercritical fluid (carbon dioxide) performs in the 
process. 
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INTRODUCTION 
 
Caignard de la Tour (1822) discovered the critical 
phenomena by observation of natural mineralization. The 
supercritical fluid technology (SCF) is based on the 
discovery of this phenomenon. Although the SCF is 
known since late nineteenth century, the basic concept of 
rapid expansion of supercritical solutions (RESS) was 
first described by Hannay and Hogarth (1879), in a study 
of the solubility of metal chlorides in supercritical ethanol 
to understand natural mineralization, observed by 
Caignard de la Tour (1822), in this study the authors 
reported the great power of SCF solvation. However, was 
Worthy (1981) whom steered the study of SCF to 
optimize micromeritic of organic materials difficult to form 
powders. 
For more than one hundred years the broad assortment 
of techniques, limitation of the equipment and specific 
conditions to achieve the supercritical state made an 
accelerated advancement scientific research difficult 
(Berche et al., 2009). The concept of SCF technology as 
said by Jung and Perrut (2001) was better understood 
and developed after the pioneering work of Krukonis 
(1984) and, especially, by the disclosure of the Battelle 
Institute's research (Smith, 1985; Petersen et al., 1986; 
Matson et al., 1987a, b), they described and modeled 
flow pattern and nucleation process at supercritical 
conditions. Since then, many methods using this 
technology have been published and patented. 
A supercritical solvent is one that at a certain 
temperature and pressure, does not condense or 
evaporate, it exists as a fluid  (Yasuji  et  al.,  2008).  This
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happens when a substance is high above its critical 
temperature and pressure, and passes it to a condition 
called ―supercritical fluid state‖. Under these conditions, 
the densities of the liquid and vapor are identical, and for 
this reason the meniscus, on the interface between the 
two phases, disappears (Moribe et al., 2008). 
In SCF conditions, substances exhibit physical 
properties that are intermediate between gases and 
liquids of the start material. Thus, the density of a SCF 
can be altered by the variation of the pressure applied on 
the fluid. When the fluid is compressed at high 
temperatures it can have a density varying between 
those displayed by gases up to typical values of liquids. 
Likewise, a SCF maintained at a relatively high density 
has the ability to dissolve a variety of materials, exactly 
as conventional liquids do, but with the power of gases 
penetration (Chan and Kwok, 2011). 
The use of environmentally more acceptable 
intermediaries, such as carbon dioxide (CO2) and water, 
is an advantage of SCF technology. The SCF most used 
in pharmaceutical applications is the CO2, due to its low 
cost and also because of its supercritical milder condition, 
which enables the processing of pharmaceuticals and 
other thermolabile raw materials (DeSimone, 2002). 
Increased bioavailability of poorly-soluble molecules, 
development of modified release systems of drugs, and 
drug delivery via oral, pulmonary or transdermal - which 
are less invasive than the parenteral route – are the main 
objectives of the pharmaceutical industry. These 
objectives can be achieved by SCF technology which 
demonstrates dramatic change in the solid morphology 
after processing, that is, medium-size and particle size 
distribution, particle shape and porosity, and, 
consequently, surface area and dissolution rate are often 
quite different from those of the starting material (Perrut, 
2003). 
The supercritical CO2 (SC-CO2) is easily obtained in 
critical temperature (Tc) of 304K and critical pressure (pc) 
of 7.38 MPa (Yasuji et al., 2008) but there are other 
substances such as nitrogen, ethanol and water, which 
also have interesting solvent properties in its supercritical 
state. However, for reasons of cost, danger of explosion, 
flammability, toxicity and adverse physical properties 
(conditions for Tc and pc too high), these substances are 
less used commercially (Maul, 1999). 
Currently, the SCF technology is an alternative for 
application in drug release technology, in addition to 
meeting the principles of green chemistry, who’s most 
accepted definition (Anastas and Warner, 1998)is "the 
design, development and implementation of chemical 
processes and products to reduce or eliminate hazardous 
substances to human health and the environment". This 
definition has been expanded by Poliakoff et al. (2002) in 
12 principles. 
The traditional methods for developing drug delivery 
systems, either in micro or nanoscale, using technologies 
such as co-precipitation, coacervation and solvent 
evaporation polymerization, use large amounts of organic 
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solvents and/or surfactants which, in general, are harmful 
to the environment (Kawashima et al., 1989; Yoshida et 
al., 2015). The aforementioned methods used to produce 
particles which commonly exhibited low rates of drug 
entrapment and difficulties in scaling, and most often 
require further treatment to remove solvent(s) and/or 
impurities from the particles. Although the pharmaceutical 
industry shows interest in innovative technologies 
involving production of micro and nanoparticles, the 
solvent disposal strongly limits the industrial production 
and generates increased costs (Jung and Perrut, 2001). 
Hence, the subject of several studies has been about the 
development of other technologies that minimize the 
problems related to pollution, toxicity and ease of 
production scale-up (De Zordi et al., 2012). 
 
 
PROCESSES IN SCF TECHNOLOGY 
 
The SCF technology can be classified into three broad 
categories according to the use of the SCF in the 
process: (i) as solvent, (ii) as antisolvent, and (iii) 
processes that do not depend on the solvent power of 
CO2. 
 
 
SCF used as solvent 
 
Supercritical carbon dioxide (SC-CO2) density is 
extremely sensitive to minor changes in temperature and 
pressure near the critical point. The density of the SC-
CO2 is closer to that of organic liquids but the solubility of 
solids can be 3-10 orders of magnitude higher (Motonobu 
et al., 2008). 
The solvent strength of a SC-CO2 can be expressed by 
the solubility parameter which is the square root of the 
cohesive energy density and is defined rigorously from 
first principles. A plot of the solubility parameter for 
carbon dioxide versus pressure would resemble that a 
plot of density versus pressure. This confirms that the 
solvation strength of a supercritical fluid is directly related 
to the fluid density. Thus the solubility of a solid can be 
manipulated by making slight changes in temperatures 
and pressures. Another attractive feature of SC-CO2 is 
that the properties lie between that of gases and liquids. 
A SC-CO2 has densities similar to that of liquids, while the 
viscosities and diffusivities are closer to that of gases. 
Thus, a SC-CO2 can diffuse faster in a solid matrix than a 
liquid, yet possess a solvent strength to extract the solute 
from the solid matrix. 
 
 
Rapid expansion of supercritical solutions (RESS) 
 
The RESS process has been extensively investigated 
and involves two steps, solubilization followed by 
particles formation (Figure 1a). The fallout of particulate 
material is obtained by dissolution of  the  material  in  the 
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SCF to form a solution, and then this mixture is expanded 
and suddenly depressurized. This decompression causes 
a rapid increase in supersaturation, leading to rapid 
nucleation and generation of sub-micrometer sized 
particles (≤ 100 nm) (Reverchon et al., 2000). Changing 
the process variables, particularly the temperature and 
pressure of the expansion and the diameter of the nozzle, 
it is possible to control the average diameter of particles 
and their size distribution. The advantage of the RESS 
process is to present valuable commercial-scale 
applications when the solubility of material or product on 
SCF (preferably CO2) is not too small (≥ 10
-3 
kg/kg or 
mole fraction > 10
-4
). The application of RESS process is 
limited to the nonpolar compounds or of low polarity 
(Perrut and Clavier, 2003; Reverchon et al., 2007). 
The most commonly used inputs for the development of 
particulate systems are not sufficiently soluble in SC-CO2 
to make the efficient production process. Thus, it is often 
necessary to modify the RESS process, as for example, 
using an organic cosolvent (Sauceau et al., 2004; 
Chattopadhyay et al., 2007) or a cosolvent solid (Thakur 
and Gupta, 2006). 
 
 
Rapid expansion of a supercritical solution into a 
liquid solvent (RESOLV) 
 
Sun and Rollins (1998); Sun et al., (2000) and Meziani et 
al. (2005) made a simple but significant modification in 
the RESS process, using a liquid on the receiving end of 
the rapid expansion (Figure 1b). This modification was 
developed for the production of nanoscale particles. It 
has been shown that the RESOLV is, potentially, a good 
platform for the nanonization of water-insoluble drugs 
(Meziani et al., 2005; Sun et al., 2005, 2006). Although 
both, RESS and RESOLV, appear to involve a process of 
particle agglomeration, one could argue that the particle 
growth and aggregation observed in RESOLV should not 
be necessarily considered as a part of the technique, 
because they are on a longer time scale after the initial 
formation of nanoparticles. On the other hand, the growth 
of particles and aggregation in RESS happens in jet 
expansion, which differentiates it from the RESOLV 
process (Sun et al., 2005). 
Particularly, the RESOLV process makes use of a 
liquid to suppress the growth of particle in the jet 
expansion, making it possible to keep the particles in 
nanoscale. However, being the nanoparticles produced in 
suspension, these can lead to clustering and form 
aggregates. A critical issue in the particles nanonization 
of drugs through the RESOLV is to initially protect the 
formed particles of agglomeration using stabilizing agents 
(Sun et al., 2005). 
 
 
Rapid expansion from supercritical to aqueous 
solution (RESAS) 
 
Young et al. (2000, 2003) proposed  the  RESAS  system 
 
 
 
 
(Figure 1c) to overcome the problem in the difficulty of 
collecting the particles that occurs in the RESS process. 
From theoretical calculations, the RESS process could 
form particles as small as 20 to 50 nm. The inability of the 
RESS process in approaching the theoretical limit is 
probably related to the growth of particles during 
collisions in the free jet expansion (Debenedetti, 1994). 
To provide stabilization against particle growth resulting 
from collisions in the jet of expanding, Young et al. (2003) 
used an aqueous solution containing phospholipid 
vesicles mixed with non-ionic surfactant to obtain sub-
micrometer particles with high drug loading rate. 
 
 
Rapid expansion of supercritical solution with solid 
cosolvents (RESS-SC) 
 
The RESS-SC process is divided into three parts, pre-
extraction, extraction, and expansion (Figure 1d). In pre-
extraction phase, CO2 is pressurized until the desired 
pressure. In extraction phase two cylindrical vessels are 
used as extraction column, one for the solid cosolvent, 
and one for the drug. Both vessels are kept at a constant 
extraction temperature and pressure is monitored in this 
phase. In the expansion phase temperature is controlled 
to be less than 5°C. A filter of glass wool is usedat the 
end of the expansion chamber output to retain the 
particles produced in the process (Thakur and Gupta, 
2006). 
In the RESS-SC process the choice of the solid 
cosolvent is very important, due to its need in offering 
interaction to improve polar solute solubility in CO2. The 
solid cosolvent must have the following properties: (i) 
high vapor pressure enough for easy removal by 
sublimation; (ii) solid output conditions of nozzles 
(typically – 5 at 25°C); (iii) appreciable solubility in SC-
CO2; (iv) non-reactive solute with desired or SC-CO2; (v) 
non-flammable and non-toxic properties; and (vi) low 
cost. Menthol is a compound that meets all the 
requirements of solid cosolvent. Its melting point is 34 to 
36°C, with high vapor pressure, good solubility in SC-CO2 
and is widely used in pharmaceutical and food industries 
(Thakur and Gupta, 2006). 
Thakur and Gupta (2006) proposed that the solid 
cosolvent not only enhances the solubility of polar 
compounds in SC-CO2, but also avoids particle growth by 
hindering agglomeration. In their work, low solubility and 
growth by coagulation are addressed by utilizing a 
cosolvent that is solid at the nozzle exit conditions. 
 
 
SCF used as antisolvent 
 
Application of SCF as antisolvent is an alternative to the 
technique of recrystallization to processes insoluble 
solids in the SCF. This method exploits the ability of 
gases to dissolve in organic liquids, decreasing the 
―solvent power‖ of the  solvent  for  solution  components,  
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Figure 1. Schematic diagrams of the processes (a) RESS, (b) RESOLV, (c) RESAS, and (d) RESS-SC. 
 
 
 
which causes precipitation solutes (Jung and Perrut, 
2001; Knez and Weidner, 2003; Perrut et al., 2007). 
Processes using gas antisolvent differ in how the contact 
is obtained between the solution and the antisolvent 
(Jung and Perrut, 2001; Knez and Weidner, 2003). 
 
 
Supercritical anti-solvent (SAS) 
 
The process named SAS is based on the decrease of the 
solvent power from a polar organic solvent, in which the 
substrate(s) of interest (pharmaceutical active ingredient 
and/or polymer) is/(are) dissolved. The dissolution of the 
SCF in the solution greatly expands its volume, acting as 
an antisolvent, which causes the formation of crystalized 
solutes and precipitation of the substrate of interest. In 
this way, the SCF is used to extract the solvent of this 
solution (Jung and Perrut, 2001; De Zordi et al., 2012) 
(Figure 2a). 
The SAS process is easily escalated and has been 
largely studied due to its potential of micro- and 
nanoparticles production, with control of the particles size 
and morphology (Perrut and Clavier, 2003; Shariati and 
Peters, 2003; Reverchon and Adami, 2006). The 
procedure is usually carried out at  temperatures  ranging 
between 308 K and 333 K, being useful when 
thermolabile compounds need to be micronized 
(Reverchon et al., 2010). 
SAS process, with minor changes, is also known as the 
ASES or PCA. In these techniques, a SCF acts as 
antisolvent for polymer solutions, such as in the GAS 
process, but the contact mechanism is different than the 
one used in the GAS process. The polymer is dissolved 
in a liquid solvent and the solution is sprayed into a 
chamber, where anantisolvent already exists, causing 
rapid contact between the two means. This generates 
greater reason of solution supersaturation, resulting in 
rapid growth and nucleation, and consequently, causing 
smaller particles. A special advantage of this technique is 
its adaptability to continuous operation, which is 
important for large-scale production. 
 
 
Gas anti-solvent (GAS) 
 
The GAS recrystallization process or GASR (Gas Anti-
Solvent Recrystallization) was patented by Krukonis et al. 
(1994) and was recognized as a solid material 
recrystallization method from systems composed of 
solute, suitable liquid solvent, and gaseous component in 
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soluble solvent, which presence makes the solvent 
approaches or reaches a supersaturated state, 
precipitating the solute. The recrystallized material 
properties can be controlled by the parameters adopted 
in the process, among them, pressure, temperature, time, 
and gas injection flow. 
The GAS process was originally designed for 
recrystallizing solid compounds that are soluble in SCF, 
having its principle based on the solution supersaturation, 
gas supercritical solution and antisolvent contact-
induced. The role of the antisolvent is to reduce the 
solubility of compounds dissolved in solution and promote 
breakthrough, nucleation and crystal growth (Sacha et 
al., 2006). 
In the GAS process, after the introduction of the 
antisolvent gas, the boundaries of the fluid-solid and 
liquid-liquid phases are shifted, respectively, for higher 
temperature or higher pressures. As a result, the system 
was initially a homogeneous phase region that turns into 
a two-phase region, where it suffers separation, leading 
to the particles formation. A significant difference 
between the GAS and RESS processes is that the RESS 
process works with a binary system of polymer and SCF, 
while in the GAS process have a ternary system of 
polymer, organic solvent, and antisolvent gas (Yeo and 
Kiran, 2005). 
The solubility is directly related to the solvent power of 
a particular solvent for the crystallization compound, 
which may affect the breakthrough degree and nucleation 
rate when the antisolvent is added to the solution. The 
solute solubility in a solvent is determined by the 
parameters of the solute and solvent physicochemical 
properties, such as, dipole moment, dielectric constant 
and solubility coefficient (Park et al., 2006). 
 
 
Aerosol solvent extraction system (ASES) 
 
Müller and Fischer (1989) patented the ASES process 
which uses the supercritical gases properties of organic 
solvent extraction. The CO2(ℓ) is introduced in a cooled 
condenser and is pumped through a heated high 
pressure column, the column temperature can be 
adjusted with another heater and is controlled by a 
thermostatic cartridge, and pressure in the middle column 
is regulated by a magnetic valve controlled by a gauge 
pressure. Under these conditions the CO2 is expanded in 
subcritical conditions into the separation container, where 
it evaporates and is transferred to the condenser, and 
then is liquefied again (Bleich et al., 1993) (Figure 2b). 
During the time of spraying it is possible to work with 
CO2 directlyin a current or static phase. To produce the 
drug and polymer microparticles,the drug and polymer 
are dissolved or dispersed in an organic solvent and 
sprayed through an atomizing nozzle as fine droplets 
inside the column with SC-CO2. The organic solvent is 
soluble in SC-CO2, and is extracted, leading to the  
 
 
 
 
microparticles formation. The SCF dissolution in 
atomized liquid droplets is accompanied by a large 
expansion in volume and, consequently, a reduction in 
the liquid solvent power causing supersaturation and 
formation of microparticles, submicroparticles, and 
uniforms liposomes (Bleich et al., 1993; Yu et al., 2008). 
Many variants of the ASES technique were proposed in 
order to control the particles morphology and size by 
using special nozzles. The preparation of thin particles for 
pulmonary administration opens a future for new types of 
materials engineering. Nanoparticles (50 to 500 nm), 
microparticles (500 to 5000 nm) or hollow nanoballoons 
(5 to 50 µm), enabled a significant increase in the 
bioavailability of poorly water soluble drugs or 
microspheres preparation with drugs for sustained 
release (Perrut, 2000; Perrut and Clavier, 2003).  
 
 
Supercritical solvent impregnation (SSI) 
 
In the SSI process the drug is transported by a SCF and 
adsorbed onto a porous carrier. The polymers can be 
impregnated through the dissolution of the drug in SCF 
and, consequently, resulting in the mixture of the fluid 
with particles of polymers (Figure 2c).The interest in 
polymeric material by impregnation SCF stems from the 
opportunity to use high diffusivity, low surface tension 
and ease in solvent recovery for preparation of new 
polymeric materials (Kikic and Vecchione, 2003). 
 
 
Supercritical anti-solvent with drug excipient mixing 
(SAS-DEM) 
 
In the SAS-DEM process the drug particles are 
precipitated in SC-CO2 within a vessel containing, in 
addition to the SC-CO2, particles of excipient (lactose 
and/or microcrystalline cellulose) in suspended state (in 
dichloromethane), with or without a surfactant 
(polaxamer407 or sodium dodecyl sulfate), and under 
agitation (Sanganwar et al., 2010; Sathigari et al., 2011) 
(Figure 2d). The SAS-DEM process was effective in 
overcoming drug–drug particle aggregation (Sanganwar 
et al., 2010), but the product further undergo aggregation 
which can be minimized by the addition of surfactant 
(Sathigari et al., 2011). 
 
 
Supercritical anti-solvent with enhanced mass 
transfer (SAS-EM) 
 
The SAS-EM process was proposed (2001) and patented 
(2003) by Chattopadhyay and Gupta and can be used to 
fabricate micro- and nanoparticles possessing very 
narrow size distribution due to the increased mass 
transfer system (Chattopadhyay and Gupta, 2002). 
 In   the   SAS-EM   apparatus,   anultrasound   field   is 
 
 
 
 
generated by the nozzle surface and also provides a 
velocity component in the normal direction to the buccal 
surface which significantly increases the turbulence and 
mixing potential within the supercritical phase (Figure 2e), 
resulting in a high mass transfer between the solution 
and the antisolvent. The combined effect of the rapid 
mixing rate between antisolvent and solution, reduce the 
solution droplets size due to atomization, providing 
approximately particles 10 times smaller than those 
obtained from conventional SAS process (Chattopadhyay 
and Gupta, 2001, 2003). 
 
 
Solution enhanced dispersion with supercritical fluid 
(SEDS) 
 
In SEDS the SCF is used as an antisolvent agent for 
polymer solutions and dispersing agent. The SEDS 
process is similar to the semi-continue SAS process, 
which consists of spraying a solution in condensate gas 
in a pressurized vessel. However, the design of the 
nozzle of both proceedings is different. The SEDS nozzle 
features a coaxial design with a length of mixture, in 
order to improve the mass transfer and get a 
simultaneous release of the solution and the antisolvent 
(York and Hanna, 1996). 
The SEDS process is distinguished by three main 
features: (i) solution and SCF are co-introduced in a jet 
with high speed, (ii) SCF turbulent flow accelerates 
mixture and particles formation processes, (iii) solvent 
composition and SCF material in the jet stream, the 
precipitation is fixed from the mixture start point, 
providing conditions for particles formation in uniform and 
continue procedure (York and Hanna, 1996). 
The SEDS process also involves the application of 
organic solution in SC-CO2 to precipitate the solute. In 
this process the CO2 is liquefied through cooling system 
and then pumped into the precipitation vessel through the 
piston pump and heat exchanger of the outdoor coaxial 
nozzle tubule. Vessel pressure is regulated and when the 
flow rate, temperature and pressure of SC-CO2 in the 
vessel of precipitation reaches the desired values, the 
drug solution is released into the vessel of precipitation 
through the inner tubule of the coaxial nozzle (Palakodaty 
and York, 1999; Edward et al., 2001; Tabernero et al., 
2012). 
In this process, it is important to consider the different 
theoretical and experimental aspects, such as phases 
equilibrium, nucleation kinetics, hydrodynamics and mass 
transfer (Reverchon et al., 2010). It is essential to study 
the phase behavior of solids-solvent-antisolvent system, 
in order to determine the conditions under which this 
mixture lies in a single phase (supercritical phase) or 
vapor-liquid binary region. In this context, the critical 
mixing point may be defined as the pressure and 
temperature conditions at which the vapor-liquid mixture 
melts in a single supercritical phase (Franceschi et al., 
2008). 
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Atomization of supercritical antisolvent induced 
suspensions (ASAIS) 
 
In the ASAIS process the SCF is used as antisolvent and 
dispersion agent. Rodrigues et al. (2011) developed this 
process, which is a small volume of SAS process 
characterized by inline dissolution from antisolvent before 
the liquid atomization for the solvent extraction step. The 
antisolvent (CO2) is mixed with a solute solution 
contained in a small volume mixer, immediately before 
the hole in the nipple, under such conditions to cause 
precipitation of the solutes.  
The suspension generated is then treated by spray-
dried for the separation of solvent. In comparison with 
other similar techniques of producing particle, this 
approach allows a more effective control of antisolvent 
process and reduces the volume of the high-pressure 
precipitator in several orders of magnitude. The particles 
of theophylline produced by ASAIS are the polymorph 
previously obtained by conventional SAS. However, the 
normal crystalline form (non-polymorphic) is obtained 
under non-antisolvent conditions (Rodrigues et al., 2011). 
 
 
Precipitation with a compressed fluid anti-solvents 
(PCA) 
 
In the PCA process the SCF is used as antisolvent and 
dispersion agent, being an alternative way for 
micronizationin a single-stage process.Operation is either 
batchwise or semi-continuous with promising scale-up 
perspectives and particle sizes ranging from submicron to 
few microns. The drug is first dissolved in organic solvent 
and then the solution is sprayed inside, or mixed with, the 
SC-CO2 which causes the drug precipitation due to the 
solvent dissolve in CO2 (Figure 2f). The operating 
temperature and pressure are selected so the SCF is 
totally miscible with the organic solvent (Snavely et al., 
2002). 
In order to control the acute phase transition kinetics 
and produce uniform particle size distribution throughout 
PCA processing, two conditions must be met. First, there 
must be uniform conditions within the nucleation medium 
(that is, can not exist supersaturation gradients). The 
uniform conditions in the nucleation medium can be 
performed by a perfect blend of fluid, resulting in a 
homogeneous level of supersaturation and nucleation 
rate. Secondly, each formed critical stage should 
experience the same amount of time for the particles 
growth. Variations in the particle’s permanence time 
result in a fine particle size distribution, due to different 
particle growth times after primary nucleation. Mixing 
settings, used to optimize the gas mixture, allows control 
over the supersaturation’slevel and uniformity, providing 
control of the average residence time and distribution of 
the particles size (Jarmer et al., 2003). 
The design of the nozzle’s key feature is the 
combination of a swirl flow  and  achamber  micro  mix  to 
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optimize the mixture between the solvent and 
compressed antisolvent gas. PCA nozzles designed to 
optimize the gas mixture are essentially different from 
conventional spray nozzles, and enable the production of 
particles in nano scale PLLA size distribution with a 
sharper than previously possible (Jarmer et al., 2003) 
(Figure 2). 
 
 
Supercritical fluid extraction of emulsions (SFEE) 
 
In the SFEE process the SCF is used as antisolvent and 
dispersion agent, producing suspension of drug 
nanoparticles. SFEE technology combines the 
advantages of using emulsion, which controls the size of 
the particles and the surface properties, with the 
continuous extraction process for SCF (Chattopadhyay et 
al., 2006).  
Since the main control parameters are the physical 
properties of the emulsion, instead of drug 
characteristics, the development of the formula that will 
sustain the stable emulsion and ensure the particles’ 
suspension must be preformulated with caution (Yasuji et 
al., 2008). 
 
 
Processes that do not depend on the carbon 
dioxidesolvent power 
 
This category comprises all operations that do not 
depend on the solvent potency of CO2, but instead takes 
advantage of the great volume expansion and cooling 
effect produced when the CO2 is depressurized, in 
operating condition, to the ambient pressure.  
The combination of SC-CO2 technology with 
othertechnologies (such as, for example, coacervation 
and emulsion),as well with equipment for special 
methods (spray drying, specialised beaks, and freeze 
drying) could solve the problemsfor the production of 
functional particles while havingcontrol of involved 
physicochemical variables (Yasuji et al., 2008). 
 
 
Particles from gas saturated solutions (PGSS) 
 
In the PGSS process SCF employs the function of co- 
solute (Nunes and Duarte, 2011), a melted substance is 
delivered with a pressurized gas in a static mixer (that is, 
the CO2 is dissolved in organic solutions or melted 
compounds) and is expanded through a nozzle of 
ambient pressure, forming particles from saturated gas 
solutions (Brunner, 2010). 
The PGSS process offers promising prospects of 
industrial development where the SC-CO2 is used as a 
reducing viscosity agent (solute) (Fages et al., 2004) 
because it is known that an increase in viscosity and an 
unequal coating material distribution leads to a non-
uniform mixing of  carrier  material  and  coating  material,  
 
 
 
 
resulting in inefficient coating and particles with wide size 
distribution (Chattopadhyay et al., 2006). The advantages 
of techniques based especially in SAS and PGSS are the 
production of spherical nano or microparticles with 
smooth surfaces and with narrow size distribution (Sheth 
et al., 2012). 
 
 
Concentrated powder form (CPF) 
 
The products obtained with the RESS, SAS, and PGSS 
drying process typically comprise only solid compounds. 
In 1997, the so-called CPF process was proposed by 
Weidner et al. (1997; 2001) allowing the generation of 
dry, free-flowing powders, and containing a very high 
liquids content. The liquid to be turned into powder 
comes incontact with a pressurized gas and is expanded 
through a nozzle. A thin spray of dispersed liquid droplets 
is formed. A solid support material is blown into the spray 
through an inert gas. The expanding gas causes an high 
turbulence area in the case of liquid droplets and solid 
support material, which are intensely mixed (Weidner, 
2009). 
The support material is agglomerated by liquid droplets. 
If the spray tower is high enough, the agglomerated are 
formed before reaching the bottom or the wall. The 
clusters can contain up to 90% (w/w) (in some cases, 
more than liquid % (w/w)). They are continuously 
removed from the bottom of the spray tower (Weidner, 
2009). 
The CPF process was applied to more than 100 liquids 
and approximately 60 different solids vehicles (Grüner et 
al., 2003). The properties of clusters rely heavily on the 
support and liquid material properties. The supporting 
materials ability to take certain amount of fluid depends 
on its chemical composition and physical properties. The 
net uptake of transporting materials has been 
investigated in detail by theoretical and experimental view 
point (Lankes et al., 2001). 
A procedure for selecting suitable support material has 
been developed by Otto et al. (2001). The density of 
support material is an adequate quantity parameter to 
correlate the experiments on the liquid absorption. Highly 
dispersed silica with a 50 kg.m
-3
 density can connect to 
more than 90% of the liquid, while the silica, with 200 
kg.m
-3
 density, can connect to 60% in mass (Otto et al., 
2001).  
Other product properties correlated with the process 
parameters are: (i) Joule–Thomson effect in spray tower; 
(ii) inert gases are applied without oxygenation in the 
spray tower, and (iii) selected products (unsaturated fats) 
versus stability (Grüner-Richter, 2007). In addition to 
these data, there is lack of knowledge about the 
processes in the static mixer, drops formation, spray 
sintering process on spray tower, and behavior of product 
properties during long-term storage (stress) (Weidner, 
2009).  
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Figure 2. Schematic diagrams of some antisolvent processes (a) SAS, (b) ASES, (c) SSI, (d) SAS-DEM, (e) SAS-
EM, and (f) PCA.  
 
 
 
Continuous powder coating spraying process 
(CPCSP) 
 
The CPCSP is another process derived from PGSS and 
was proposed by Weidner et al. (1999), as an alternative 
technique for the manufacture of powder coatings 
(Weidner et al., 2001; Petermann et al., 2003). 
The continuously operated process is applicable to low-
melting, fast-reacting, and conventional powder coating 
systems and allows coatings production with improved 
properties. The process uses the dense gases solubility 
which has solute-solute in molten coating polymers at 
pressures up to 220 bar. In separated tanks, the single 
components of a powder coating mixture are melted and 
are dosed to a static mixer by means of high-pressure 
pumps. In the mixer, the melts are homogenized and 
simultaneously the CO2 compressed is dissolved. In the 
sequence of the  process  this  solution  is  depressurized 
over a nozzle into a spray tower. In that way, the melt is 
atomized into fine droplets and cooled by  the  expanding 
gas. The drops solidify and form fine solid particles. The 
operating parameters on the plant modify particle size, 
particle size distribution, and powders morphology 
(Weidner et al., 2001; Petermann et al., 2003). 
 
 
Supercritical enhanced atomization (SEA) 
 
The SEA technique essentially explored the CO2 
atomization enhancement in a spray drying process and 
is based on the SCF ability to improve break-up of liquid 
jets into fine droplets when simultaneously depressurized 
with liquid solutions (Padrela et al., 2010; Rodrigues et 
al., 2012). The SCF-assisted atomization is particularly 
intense, mostly due to the SCFs exhibit high densities 
and  low  viscosities,  causing  a  strong  increase  in   the  
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liquid’s momentum and interfacial shear forces 
(Rodrigues et al., 2012). The atomization of liquid jets 
assisted by a gas is a classical fluid mechanics process 
although the use of SCF for this purpose is relatively 
recent. 
 
 
Supercritical fluid-assisted atomization (SAA) 
 
The SAA was described by several researchers (Sievers 
et al., 1998; Sellers et al., 2001; Reverchon et al., 2004) 
as a process where the SC-CO2 and a drug solution (in 
water or organic solvent) are heated separately, mixed 
into the saturator and then sprayed into the vessel in 
close conditions to atmospheric pressure at a stream of 
heated nitrogen to assist liquid droplets evaporation. On 
SAA apparatus a bottling thermostat contactor is used to 
obtain a dissolution nearly the equilibrium of SC-CO2 in 
liquid solution (Reverchon et al., 2004).  
A two-step atomization is achieved: the primary 
droplets on output injector are still divided into secondary 
droplets due to expansion SC-CO2 from the inside of the 
primary. This process was used to improve the 
micronization of drugs through SCF, since with the SAS 
process for extraction some drugs presented 
unsatisfactory results (Sievers et al., 1998; Reverchon et 
al., 2004). 
 
 
Carbon dioxide assisted nebulization with a bubble 
dryer (CAN-BD) 
 
CAN-BD process originated from the SAA process and 
was patented by Sievers et al. (2003). This process has 
been shown to have wide applicability for small molecule, 
as well as for macromolecule (including therapeutic 
proteins) by obtaining dry powders with good stability and 
activity. In addition the dry powders are thin enough to be 
inhaled and reach the lungs (Cape et al., 2008). In this 
process, the drug dissolved in water or alcohol (or both) 
is mixed intimately with almost-critical or supercritical CO2 
for pumping both fluids through a low volume tube in 'T' 
to generate micro-bubbles and micro-droplets, which are 
are then uncompressed by a low-temperature drying 
chamber, where aerosol plume is dried in a few seconds. 
The CO2and solution are mixed in the 'T' at room 
temperature while the micro-bubbles and micro-droplets 
formed are quickly dried at lower temperatures (25 to 
80°C) than are used in the traditional spraying drying 
processes. The particles residence time inside the drying 
glass chamber, laboratory-scale of 750 mL, is less than 3 
s (Sievers et al., 2001, 2003).  
The best advantage of this process is that there is less 
thermally labile drug decomposition. Secondly, no high 
pressure vessels are required to proceedings CAN-BD, 
except for the syringe pump, the 1/16 inch OD stainless 
steel tube, the 'T' of low volume and flow limiter, which 
allow the fluid mixture  to  a  moderate  pressure  (that  is,  
 
 
 
 
between 80 and 100 bar), and the micro-bubbles and 
micro-droplets expansion at atmospheric pressure.  
Thirdly, these particles are generally formed in a suitable 
size distribution for the release in the pulmonary alveoli 
(Sievers et al., 2003, 2007). 
 
 
PGSS drying 
 
In a different approach named PGSS drying, which the 
SCF exerts the co-soluto and propellant function,the 
particles need not be dried through a stream of heated N2 
as in CAN-BD and SAA processes. Instead, the solvent is 
removed from the spray tower along with the gas, and a 
free flowing powder precipitates at low temperatures (30 
to 60°C) in an inert oxygen-free atmosphere which is 
particularly important when processing oxidation-
sensitive substances (Weinreich et al., 2002; Nunes and 
Duarte, 2011). Such as in the PGSS process, the liquid 
solution to drought is intensely mixed with SC-CO2 using 
a static mixer at desired temperature and pressure. The 
mixture is expanded in a nozzle into a spray tower, in 
which its conditions are adjusted in a method that the 
solvent is removed together with the gas. Super heating 
the mixture under pressure promoted adjusts in the spray 
tower temperature. The post-expansion temperature 
must at least be higher than the dew point in the gas and 
solvent binary system. In that case, solvent and gas form 
a homogeneous phase being removed from the spray 
tower and fine droplets are formed, due to expansion of 
CO2 because atmospheric conditions. In addition, 
evaporation of residual solvent takes place due to the 
pre-selected temperature conditions in the spray tower 
(Weidner, 2009). If mixture as a liquid solvent is used, the 
equilibrium phase data of multicomponent system are 
required to determine the appropriate conditions to attain 
the precipitation (Meterc et al., 2007; 2008). 
 
 
Depressurization of an expanded liquid organic 
solution (DELOS) 
 
DELOS is a single-step process, being employed in direct 
production of micro- or sub micrometer crystalline 
particles. This method is based on experienced high 
temperature, and the fast and very evenly decremented 
mass of an organic solution, previously expanded with a 
compressed CO2, when is depressurized. Through the 
process DELOS, it is possible to achieve the reduction in 
size of different types of organic compounds that are 
difficult to spray through conventional techniques, 
according to the Ventosa et al. (2001). This process, 
patented by Ventosa et al. (2002), in which the SCF act 
as cosolvent being completely miscible, at a given 
pressure and temperature, with the organic solution of 
the solute to be crystallized. According to authors, the 
role of the SCF is to produce a homogenous sub cooling 
of the solution with the precipitation of solid particles. 
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Table 1. Pharmaceutical applications of SCF.SCF category, process name, organic solvent use, process type, critical factors in the process, and type of produced particles. 
 
SCF category Process name Organic solvent Process type Critical factors* Type of produced particles References 
S
ol
ve
nt
 RESS No  Continue a, b, c, d Micro or nanoparticles and compound particles Krukonis (1984), Türk et al. (2002) 
RESOLV No Continue a, b, c, d, f Nanoparticles Meterc et al. (2008) 
RESAS No Continue a, b, c Nanoparticles Young et al. (2000; 2003) 
RESS-SC or CSS No Discontinue a, b, c, h, i Nanoparticles Thakur and Gupta (2006) 
       
A
nt
i-s
ol
ve
nt
 
SAS Yes  Semi-continue a, e, i, j Micro ou nanoparticlesandcompoundparticles Yeo et al. (1993), Reverchon et al.  (2003) 
GAS Yes Discontinue a, e, i, j Micro or nanoparticles and compound particles Warwick et al. (2000) 
ASES Yes Semi-continue a, b, c, e, i, j Micro or nanoparticles and compound particles Bleich et al. (1993), Kunastitchai et al. (2006) 
SSI Yes Discontinue a, b, c, e,  h, i Polymer particles impregnated with drug Kikic and Vecchione (2003) 
SAS-DEM Yes Semi-continue a, i, e, j, m Micro or nanocompound particles Sanganwar et al. (2010), Sathigari et al. (2011) 
SAS-EM Yes Semi-continue b, e, f, j Nanoparticles and compound particles Chattopadhyay and Gupta (2001; 2002) 
SEDS Yes Semi-continue a, b, c, e, i, j Microparticles and compound particles Yorkand Hanna (1996) 
ASAIS Yes Semi-continue a, c, e, i, j Microparticles and compound particles Rodrigues et al. (2011) 
PCA Yes Continue b, e, j Micro or nanoparticles and compound particles Snavely et al. (2002) 
SFEE Yes Continue a, e, f, i, j Microparticles and compound particles Yasuji et al. (2008) 
       
O
th
er
 
PGSS No Continue or Discontinue c, n Micro or nanoparticles and compound particles Wendt (2007) 
CPF Yes Continue b, e, f, j Dried powders, free flowing and of high liquid content 
Petermann et al. (2001), Weinreich et al. 
(2002) 
CPCSP No Continue or Discontinue a, b, c, i, j, o Coated powders Weidner et al. (2001) 
CAN-BD Water and/or alcohol Continue a, b, c, e Nanoparticles and compound particles Sievers et al. (2003) 
SAA Yes Continue a, c, e, i, j, n, o Microparticles and compound particles Reverchon (2007) 
SEA No Continue a, c, i, j Microparticlesandcompoundparticles Padrela et al. (2010) 
PGSS drying Yes Continue a, e, f, l, o Microparticles Meterc et al. (2007) 
DELOS Yes Discontinue a, b, c, d, e, h, i Micro or nanoparticles Ventosa et al. (2001) 
 
*FSC factors for particles production: (a) material solubility on FSC, (b) pre-expansion condition, (c) spray device, (d) particulate material aggregation, (e) co-solvent type, (f) choice of plasticizer, (g) 
diffusion propriety, (h) eutectic propriety, (i) solvent extraction, (j) mass transfer, (l) viscosity, (m) properties of the carrier material and liquid, (n) liquid solution concentration, (o) choice of temperature. 
 
 
 
The DELOS process includes three steps: (i) 
dissolution of the solute to be crystallized in con-
ventional organic solvent, at atmospheric pressure 
and room temperature to form concentrated 
solution of solute, which is below the saturation 
limit. (ii) addition of CO2 in the organic solution to 
obtain an volumetric expanded liquid solution at 
high working temperature and pressure. The so-
lute concentration in this step must  remain  below 
the limit of saturation in the mixture expanded on 
conventional solvent and CO2 (iii) rapid reduction 
of the expanded solution pressure, from the 
atmospheric pressure through a check valve 
(Ventosa et al., 2001; 2002). During depressuri-
zation process, the CO2 evaporation from the 
expanded solution takes place producing a signi-
ficant volume decrease, in a fast and extremely 
homogeneous  temperature  of  the   solution   up  
to the final temperature. As a result, a sharp and 
homogeneousincrease of supersatu-ration ratio 
over the entire solution takes place and the 
phenomenon of catastrophic nucleation occurs 
causing the precipitation of submicron or micron 
sized crystalline particles with a narrow particle 
size distribution (Ventosa et al., 2001, 2002). 
Table 1 shows the classification of SCF 
technology,  in  which  is  described   the   process
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type of SCF, SCF process critical factors for the 
production of particles and possible type of particles that 
can be produced. 
 
 
CONCLUSION 
 
There are two basic approaches, RESS and SAS 
techniques, for the production of pharmaceutical micro or 
nanoparticles by theSCF technology, where the SCF acts 
as solvent or anti-solvent in the RESS and SAS 
processes, respectively. Changing the RESS process, 
particularly modifying the contents of the receiving end 
vessel, increasing the number of expander vessels in the 
process or others modifications which increases mass-
transfer rate, it is possible to create a new process. 
However, in many cases, the SAS process is the most 
suitable because it does not require that the solute is 
soluble in the SCF as required by the RESS technique. 
The SAS process received incremented technological 
innovations generating derivatives processes, especially 
modifying the atomization efficiency. The SCF technology 
in the pharmaceuticals application process cannot 
depend on the SCF solvent power, but other factors, 
such as the volume expansion or association with other 
technologies, give rise to new processes. After 
witnessing a steady growth of this technology over the 
last 35 years, it is expected in a near future for major 
investments to happen in facilities related to the 
production and also the development of other innovative 
applications, interestingly not only for the  pharmaceutical 
industries but also for the academia. 
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